+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Drug-Eluting Stents - Global Market Trajectory & Analytics

  • ID: 338541
  • Report
  • May 2020
  • Region: Global
  • 362 Pages
  • Global Industry Analysts, Inc
1 of 2
Amid the COVID-19 crisis and the looming economic recession, the Drug-Eluting Stents market worldwide will grow by a projected US$1.8 Billion, during the analysis period, driven by a revised compounded annual growth rate (CAGR) of 4%. Polymer-Free, one of the segments analyzed and sized in this study, is forecast to grow at over 4.3% and reach a market size of US$5.1 Billion by the end of the analysis period. An unusual period in history, the coronavirus pandemic has unleashed a series of unprecedented events affecting every industry. The Polymer-Free market will be reset to a new normal which going forward in a post COVID-19 era will be continuously redefined and redesigned. Staying on top of trends and accurate analysis is paramount now more than ever to manage uncertainty, change and continuously adapt to new and evolving market conditions.

As part of the new emerging geographic scenario, the United States is forecast to readjust to a 2.6% CAGR. Within Europe, the region worst hit by the pandemic, Germany will add over US$44.8 Million to the region's size over the next 7 to 8 years. In addition, over US$45.4 Million worth of projected demand in the region will come from Rest of the European markets. In Japan, the Polymer-Free segment will reach a market size of US$255.9 Million by the close of the analysis period. Blamed for the pandemic, significant political and economic challenges confront China. Amid the growing push for decoupling and economic distancing, the changing relationship between China and the rest of the world will influence competition and opportunities in the Drug-Eluting Stents market. Against this backdrop and the changing geopolitical, business and consumer sentiments, the world’s second largest economy will grow at 7.6% over the next couple of years and add approximately US$572.3 Million in terms of addressable market opportunity. Continuous monitoring for emerging signs of a possible new world order post-COVID-19 crisis is a must for aspiring businesses and their astute leaders seeking to find success in the now changing Drug-Eluting Stents market landscape. All research viewpoints presented are based on validated engagements from influencers in the market, whose opinions supersede all other research methodologies.

Competitors identified in this market include, among others:

Abbott Laboratories, AlviMedica, Arterius Limited, Biotronik SE, Boston Scientific Corporation, Cook Medical, Medtronic plc , STENTYS SA, Terumo Corporation

The global analysis and forecast periods covered within the report are 2020-2027 (Current & Future Analysis) and 2012-2019 (Historic Review). Research estimates are provided for 2020, while research projections cover the period 2021-2027.
Note: Product cover images may vary from those shown
2 of 2
I. INTRODUCTION, METHODOLOGY & REPORT SCOPE

II. EXECUTIVE SUMMARY

1. MARKET OVERVIEW
Coronary Stents Market - A Prelude
Recent Market Activity
Competitive Scenario
J&J Exit from DES Market Improves Prospects for Competitors
Evolution of the Drug-Eluting Stent
Evolution of Drug-Eluting Stents (DES) Over the Years
Comparative Analysis of Drug-Eluting Stents in Terms of Physical Parameters
Bioabsorbable Stents
New Stents with Biodegradable Polymers
Completely Bioresorbable Scaffolds: Potential Game-Changer
Noteworthy Clinical Studies and Innovations
Study Proves Efficacy of Very Thin Strut DES On Par with Durable Polymer Stents
Drug-Eluting Stents and Drug-Coated Balloons for Non-Coronary Indications
DES for Large Sized Arteries
Addressing the Unmet Challenges in Patients with Diabetes
Biosensors Commercializes BMX-J DES System
SLENDER DES Set to Downsize the Future of Interventional Cardiology
Other Novel DES Launches
Researchers at University of Strathclyde Evaluate VAN 10-4 Small Molecule
DES Safe for Vein Grafts Procedures
Global Competitor Market Shares
Drug-Eluting Stents Competitor Market Share Scenario Worldwide (in %): 2018 & 2029
Impact of Covid-19 and a Looming Global Recession

2. FOCUS ON SELECT PLAYERS
Abbott Laboratories (US)
AlviMedica (Turkey)
Arterius Limited (UK)
B. Braun Melsungen AG (Germany)
Biosensors International Group, Ltd. (Singapore)
Shandong JW Medical Systems LTD. (China)
Biotronik SE & Co. KG (Germany)
Boston Scientific Corporation (US)
Cook Medical Inc. (US)
Elixir Medical Corp. (US)
KYOTO MEDICAL PLANNING Co., Ltd. (Japan)
Lepu Medical Technology (Beijing) Co., Ltd. (China)
Medtronic plc (Republic of Ireland)
Micell Technologies, Inc. (US)
Opto Circuits (India) Ltd (India)
Eurocor GmbH (Germany)
OrbusNeich Medical Company Limited (Hong Kong)
QualiMed (Germany)
Shanghai MicroPort Medical (Group) Co., Ltd. (China)
Sino Medical Sciences Technology Inc. (China)
STENTYS SA (France)
Terumo Corporation (Japan)

3. MARKET TRENDS & DRIVERS
Key Market Drivers & Restraints
Aging - A Key Market Driver
Global Aging Population Demographic Statistics: Key Opportunity Indicator
High Diabetes Incidence Worldwide Drives Demand for Cardiac Surgery and Stents

4. GLOBAL MARKET PERSPECTIVE

III. MARKET ANALYSIS

GEOGRAPHIC MARKET ANALYSIS

UNITED STATES
Market Facts & Figures
US Drug-Eluting Stents Market Share (in %) by Company: 2018 & 2025
Market Analytics
CANADA
JAPAN
CHINA
EUROPE
Market Facts & Figures
European Drug-Eluting Stents Market: Competitor Market Share Scenario (in %) for 2018 & 2025
Market Analytics
FRANCE
GERMANY
ITALY
UNITED KINGDOM
SPAIN
RUSSIA
REST OF EUROPE
ASIA-PACIFIC
AUSTRALIA
INDIA
SOUTH KOREA
REST OF ASIA-PACIFIC
LATIN AMERICA
ARGENTINA
BRAZIL
MEXICO
REST OF LATIN AMERICA
MIDDLE EAST
IRAN
ISRAEL
SAUDI ARABIA
UNITED ARAB EMIRATES
REST OF MIDDLE EAST
AFRICA

IV. COMPETITION
Total Companies Profiled: 35
Note: Product cover images may vary from those shown
3 of 2

Loading
LOADING...

Adroll
adroll